Clinical trial

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

NCT02299765

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2014-12-01

PhasePHASE4

Study timeline

Study start (actual)2014-12-01Date precision: month

Registry last updated2017-11-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancer Metastaticunresolved

EGFR Activating Mutationunresolved

Interventions

GefitinibDRUG · verified · RxNorm: gefitinib

gemcitabineDRUG · verified · RxNorm: gemcitabine

carboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Sichuan Universitylead sponsor

AstraZenecacollaborator

Mapped research locations

ChengduSichuan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02299765 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.